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INTRODUCTION
Psoriasis is a chronic relapsing skin disease, affecting
0.2–4.8% of the world population. The lowest prevalence is
in Asian countries, and the highest — in Scandinavia
(Duffin et al., 2010), in the Baltic countries — 4% (Ivdra,
2010). It is a genetically determined, multifactorial
dermatosis and significant role in its development is played
by genetic, immune, and environmental factors (Hartmane,
2004). Clinical presentations of the disease are erythe-
matous and papulous lesions with infiltration and extensive
desquamation on the surface. Nowadays, it has been proved
that keratinization, the main function of the epidermal layer
of the skin, has the crucial significance in the pathogenesis
of psoriasis that is determined by apoptosis of keratino-
cytes, as well as alteration in the process of proliferation
and differentiation of these cells. Such changes explain the
numerous immunological conceptions of the development
of psoriasis (Bowcock and Krueger, 2005). The leading
immunopathogenetical mechanism is psoriasisis migration
of T lymphocytes with lypmphocytary antigen in the skin
after their common interaction with epidermal antigen pre-
senting cells in regional lymph nodes. The skin infiltrating
T-lymphocytes, monocytes, macrophages, and keratinocytes
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Psoriasis is a chronic relapsing skin disease presenting with erythematous and papulous lesions
with infiltration and extensive desquamation on the skin surface. It is a genetically determined,
multifactorial dermatosis where genetic, immune, and environmental factors play significant roles
in its development. In Latvia in treatment of different forms of extensively spreading psoriasis,
PUVA (psoralen and ultraviolet A light therapy), a combined method, is administered, applying
long-wave UVA radiation with wavelength 320–400 nm in combination with photosensibilisator 8-
metoxypsoralen and medium wave length UVB radiation narrow-band phototherapy — 311 nm
using specialised TL-01 lamps. The aim of our clinical investigation was to determine the efficacy
of narrow-band phototherapy (UVB 311 nm) in the complex treatment of patients with different se-
verity of extensive psoriatic lesions treated in the Clinical Centre of Skin and Sexually Transmitted
Diseases. Cases of clinical data of 260 patients with widely spread psoriasis were analysed. In
the Group 1 (n = 102) receiving narrow-band UVB therapy, the mean and cumulative UVB dos-
age was 1.8 ± 0.6 and 21.5 ± 3.8 J/cm2, respectively, whereas in Group 2 (n = 91) it was 2.2 ±
0.1 and 27.7 ± 8.0 J/cm2. To obtain clinical recovery, 18 to 30 procedures were necessary (aver-
age 22 ± 4.1) with total irradiation dose received 110 ± 4.6 J/cm2. In 67 patients of the control
group, PUVA therapy was administered, and positive therapeutic efficacy was observed in all pa-
tients. Clinical recovery was obtained in 86.2% in patients of the Group 1, in 82.4% — of Group 2,
and in 80% — in 67 patients of the control group. Narrow-band (311 nm) UVB phototherapy is
currently one of the leading pathogenetical methods of treatment of patients with widespread pso-
riasis. It has high efficacy, good tolerability, does not have severe side effects and restrictions in
use, in comparison with traditional PUVA therapy.
Key words: psoriasis, UV therapy, phototherapy, PUVA (combination of psoralen and long-wave
ultraviolet radiation), PASI (Psoriasis Area and Severity Index).
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produce anti-inflammatory cytokines that promote hyper-
proliferation of keratinocytes and alterations in their differ-
entiation (Hartmane et al., 2001). Therefore, the main
pathophysiologic processes in psoriasis include hyperplasia
of epidermis with alterations in differentiation of keratino-
cytes as well as inflammatory reaction in dermis.
One of the most effective methods of psoriasis treatment is
different spectrum (according to wavelength) ultraviolet
(UV) radiation therapy or phototherapy (Lapolla et al.,
2011). In Latvia in treatment of different forms of exten-
sively spreading psoriasis, PUVA (a combined method,
psoralen and UVA treatment), is administered, applying
long-wave UVA radiation with wavelength 320–400 nm in
combination with photosensibilisator 8-metoxypsoralen and
medium wave length UVB radiation narrow-band photo-
therapy — 311 nm using specialised TL-01 lamps (Anony-
mous, 2014). The substantiation of the efficacy of photo-
therapy is its immunomodulatory influence with the
prevalence of immunosuppression (Ulrich and Byrne,
2012). The main immunologic effects of phototherapy are:
1) induce apoptosis or programmed cell death in cells
pathogenically responsible for development of psoriasis
(Langerhans cells in epidermis, dendritic cells in the skin,
keratinocytes, T lymphocytes);
2) suppress the activity of adhesion molecules on antigen
presenting cells;
3) inhibition of mitotic activity of T lymphoid cells in the
skin and dermal capillaries;
4) promote production of immunosuppressive and anti-
inflammatory mediators and cytokines.
Several publications have demonstrated that narrow-band
UV radiation therapy has more intensive immunosuppres-
sive and anti-inflammatory action (Kostovic and Pasic,
2004; Parsed et al., 2006). Absolute contraindications in
phototherapy are genetic pathologies with increased light
sensitivity with consecutive higher risk for development of
skin cancer, hard-going somatic diseases in decompensated
stages. Prior to start of UV therapy, it is recommended to
determine the individual light sensitivity, specifying the
minimal erythemal dose (MED) (Barbagallo, 2001). In der-
matological praxis in predominant cases, standardised thera-
peutical schemes are applied, starting with a single dose of
phototherapy and then increasing the dose, taking into ac-
count the phototype of the skin (Menter et al., 2010, Archier
et al., 2012). In Latvia phototherapy is administered, based
on standardised guideline protocols based on phototype of
the skin, not determining the individual MED (Anonymous,
2013).
The aim of our clinical investigation was to determine the
efficacy of narrow-band phototherapy (UVB 311 nm) in the
complex treatment of patients with different severity of ex-
tensive psoriatic lesions treated in Clinical Centre of Skin
and Sexually Transmitted Diseases from 2008 till 2013.
MATERIALS AND METHODS
Patients. Cases of clinical data of 260 patients with widely
spread psoriasis were analysed. Of these, 167 were male
and 93 were female patients, with age 14 to 72 (mean age
28 ± 11.4 years). Duration of the disease varied from 7
months to 36 years (mean duration 16.0 ± 7.8 years). Pso-
riasis vulgaris form was diagnosed in 187 (72%) patients,
but psoriasis exudativa form in 73 (28%) patients. Disease
in the progressive stage was detected in 62 (24%) and in
stationary stage in 156 (60%) patients. Torpid stage was di-
agnosed in 42 (16%) patients, presenting with exacerbations
from 2 till 5 times per year having short periods of remis-
sion from 3 weeks till 4.5 months, as well as slow remission
of psoriatic lesions during the treatment period. Narrow-
band UVB phototherapy was used to treat 193 patients (106
male and 87 female), aged from 14 to 68 years and the dura-
tion of the disease from 7 months to 34 years. For analysis
of clinical data, patients were divided into two groups and a
control group, taking into account the grade of severity of
psoriasis (Fig. 1). Group 1 (major group) included 102 pa-
tients with mild and medium forms of psoriasis, whose
PASI (Psoriasis Area and Severity Index) at the start of
treatment were from 7 till 18 points. Group 2 (comparison
group) included 91 patients with severe psoriasis with PASI
varying from 22.0 to 48.6 points. There were 67 patients in
the control group.
Procedures. Narrow-band (311 nm) UVB phototherapy
procedures were performed 2 to 5 times a week, in line with
the accepted protocol. The starting UV radiation dose was
0.1–0.2 J/cm2, depending on skin phototype. Radiation dos-
age was increased by 0.1 J/cm2 in every next procedure. In
case of development of mild erythema, the dosage remained
the previous.
Phototherapy was performed in complex with systemic
anti-inflammatory and local medications for treatment of
psoriasis — via intravenous infusions of Sol. Haemodesi
and Sol. Natrii chloridi 0.9%, 10% Sol. Calcii gluconatis,
30% Sol. Natrii tiosulphatis. Topical antipsoriatic creams
and ointments were applied.
In the control group, data of 67 psoriasis patients (44 male
and 23 female) treated with PUVA therapy were analysed.
Age of patients in this group varied from 18 to 72 years; du-
ration of the disease was from 3 to 36 years. For these pa-
tients the PASI index before the start of therapy varied from
24.0 to 50.9 points. PUVA therapy procedure was per-
formed 2–3 times a week according to the treatment proto-
col. In these cases, a photosensitising agent — 8-metho-
xypsoralen (meladinin) was administered 1 hour before UV
irradiation 0 per os in dosage 0.6 mg/kg. The initial dosage
of irradiation was 0.3–0.75 J/cm2. In the consecutive UVA
irradiation procedures dosage was increased after every 1–3
procedures by 0.25–0.5 J/cm2.
Both groups of patients treated with narrow-band UVB pho-
totherapy statistically did not differ from the control group
that received PUVA therapy. These groups did not differ in
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age, or in the form of psoriasis, or in the duration of the dis-
ease. Patients from Group 2 and the control group were
comparable by means of severity of onset of the disease.
Clinical manifestation of psoriasis was evaluated in the be-
ginning and at the end of the treatment course. The efficacy
of treatment was detected taking into account the stage of
regression of psoriatic lesions (Table 1).
Data processing methods. Statistical analysis of clinical
data and obtained results was performed, determining the
arithmetic mean (M), average arithmetic error (m) and aver-
age square deviation (s). To define statistically significant
differences among the mean values, Student (t) coefficient
and non-parametric batch file criterion were applied. To
evaluate the efficacy of therapy the changes in PASI values
were compared between the two groups of patients, treated
with UVB phototherapy and PUVA. T test was applied to
compare two independent selections. Significant differences
were considered if p < 0.05. Before application of the com-
parison test the correspondence of all the selections to nor-
mal distribution was checked by non-parametrical one fac-
tor test of Kolmogorova–Smirnova, as well as by percentile
and quartile — P-P and Q-Q curves.
Duration of treatment course with narrow-band middle
wave length UVB therapy (311 nm) was individual and de-
pended on the speed of absorption of psoriatic lesions and
time of regression onset. In Group 1 receiving narrow-band
Parameters UVB (311nm) (PASI < 20)
Group 1 (n=102)
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PASI index 10.2±9.4 24.6±8.8 28.6±11.3
Remark. *- mean error (M+/-m)
Fig. 1. Clinical parameters of psoriasis patients
T a b l e 1
CRITERIA OF EFFICACY OF PHOTOTHERAPY
Criterion Clinical description
Clinical recovery Total regress of psoriatic lesions
Obvious improvement Regress < 85% of lesions; in the biggest psoriatic
plaques persistent infiltration
Improvement Regress > 85% of lesions; in the biggest psoriatic
plaques insignificant infiltration
Without efficacy Resolution of psoriatic lesions 15%
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UVB therapy the mean and cumulative UVB dosage was re-
spectively 1.8 ± 0.6 and 21.5 ± 3.8 J/cm2, whereas in Group
2 — 2.2 ± 0.1 and 27.7 ± 8.0 J/cm2. The number of proce-
dures in Group 1 varied from 10 to 25 (average 20 ± 4.5), in
Group 2 from 20 to 35 (average 25 ± 5.2) (Table 2).
RESULTS
Regress of the psoriatic process was observed on average
after 10–12 procedures. In 142 (74%) of patients, resolving
of psoriatic lesions started from the peripheral part of le-
sions, and in 51 (26%) from the centre of the lesion. Smaller
elements with minor infiltration resolved and regressed
faster than those lesions with deeper infiltration. Obvious
positive improvement was detected in lesions localised on
the face, trunk and upper extremities. Slower resolving and
regress of psoriatic lesions were observed in lesions local-
ised on lower extremities. Positive efficacy of therapy was
observed in all patients who received UVB phototherapy
(Fig. 2). The overall tolerance of phototherapy was good. In
14 (7.2%) patients, barely susceptible erythema was ob-
served, and in 8 (4.1%) — moderate severe itching of skin.
After administering PUVA therapy, positive therapeutic ef-
ficacy was observed in all patients (Fig. 2). To obtain clini-
cal recovery, 18 to 30 procedures were necessary (average
22 ± 4.1) with total irradiation dose received 110 ± 4.6
J/cm2. No statistically significant differences were observed
in a number of therapeutic procedures between the patients
who received UVB therapy and the patients who received
PUVA therapy (control group) (p > 0.05) (T test for com-
parison of two independent groups). However, in the case of
PUVA therapy, the number of side effects was more numer-
ous and more severe. Twelve (17.9%) patients developed
erythema and moderate itching of the skin, five (7.4%) pa-
tients had headaches and eight (11.9%) of patients suffered
from nausea as a side effect of photosensibilising medica-
tion.
Clinical recovery was obtained in 86.2% of patients of
Group 1, in 82.4% of Group 2, and in 80% of patients of the
control group.
Statistically significant differences in PASI percentage im-
provement were not observed between groups of patients
who received narrow-band UVB 311 nm and phototherapy
(p > 0.05) (Fig. 2) (T test to compare two independent
groups).
DISCUSSION
The obtained results show the high clinical efficacy of the
narrow-band middle wavelength (311 nm) UVB photo-
therapy in the treatment of patients with widespread psoria-
sis. By efficacy, this method is not weaker than the slightly
T a b l e 2
DOSAGES OF NARROW-BAND UVB AND PHOTOTHERAPY
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102 88 (86.2%) 14 (13.8%) 0 0
2nd. group
of UVB
91 75 (82.41%) 13 (14.28%) 3 (3.29%) 0
PUVA 67 54 (80.59%) 9 (13.43%) 4 (5.97%) 0
Fig. 2. Clinical results of UVB (311
nm) and PUVA therapy in patients
with widespread psoriasis
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older method of traditional PUVA therapy. Furthermore,
there were less patients in the control group (see the com-
parative literature data on UVB and PUVA therapy, Archier
et al., 2012). By applying PUVA photochemical treatment,
remission of psoriasis was achieved by controlled induction
of photochemical reactions in the skin, which was achieved
by UVA-induced photo activation of psoralens. The major
problem of PUVA therapy is the risk of development of nu-
merous long-term side effects caused by photochemical re-
actions. The most common of them are premature aging of
the skin and photocarcinogenesis. Signs of premature aging
caused by PUVA therapy are dryness and wrinkling of the
skin, and development of telangiectasias and keratosis,
which are irreversible and aesthetically unacceptable for pa-
tients. Moreover, non-melanoma skin cancer in patients af-
ter administration of PUVA phototherapy develops 10 times
more often than in the overall population. Several publica-
tions have confirmed increased risk for the development of
melanoma as the result of received PUVA therapy. Studies
on animals have shown carcinogenic effect of UVB and the
premature aging of the skin, although when compared to
PUVA, the risk of development of skin cancer was obvi-
ously lower. Narrow-band UVB phototherapy has been
more often administered in the dermatological praxis at the
Clinical Centre of Skin and Sexually Transmitted Diseases
during the last three years. Unlike PUVA therapy, in the
case of UVB therapy it is not necessary to administer
photosensitising medication, thus decreasing the number of
side effects.
Our study showed that to achieve remission of psoriasis, an
equal number of UVB and PUVA procedures were neces-
sary. Furthermore, the dose of UVB was significantly lower
than the dose of UV radiation received during PUVA ther-
apy (Table 2). Due to the smaller dose of UVB radiation,
the number of cases of development of erythema as a ther-
apy side effect was lower. Thus, UVB phototherapy was
better accepted by patients. The advantage of UVB therapy
is that this method can be prescribed to psoriasis patients to
whom PUVA therapy is contraindicated due to other so-
matic diseases. Narrow-band UVB phototherapy in compar-
ison to PUVA is economically more cost-effective, it does
not require psoralens, it can be prescribed to pregnant pa-
tients and children under 18 years of age, and there is no ne-
cessity for eye protection during treatment period (Dawe,
2003).
After analysis of data from the Clinical Centre of Skin and
Sexually Transmitted Diseases it can be concluded that nar-
row-band (311 nm) UVB phototherapy currently is one of
the leading pathogenetical methods of treatment of patients
with widespread psoriasis. We recommend UVB photo-
therapy as the method of choice in the treatment of moder-
ate and severe forms of psoriasis, as it is as effective as
PUVA, it is better tolerated and has fewer side effects.
PUVA is recommended in cases of an infiltrative form of
psoriasis, as UVA radiation penetrates deeper into human
skin than UVB. PUVA therapy if preferable in cases when a
patient presents long-term torpid occurrence of psoriatic le-
sions, shows photosensibilisation against UVB, and has ac-
tive aggressive onset of psoriasis with inflammatory com-
ponent.
CONCLUSIONS
Narrow-band UVB phototherapy has high efficacy, good
tolerability, and does not have severe side effects and re-
strictions in use, in comparison with traditional PUVA ther-
apy. It has to be the method of the first choice for treatment
of moderate and severe psoriasis.
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FOTOTERAPIJAS LIETOÐANAS PIEREDZE DERMATOLOÌISKAJÂ PRAKSÇ PSORIÂZES PACIENTU KOMPLEKSÂ
ÂRSTÇÐANÂ
Psoriâze ir hroniski un recidivçjoði norisoða, ìençtiski nosacîta, multifaktoriâlas dabas âdas slimîba, un tâs attîstîbâ liela nozîme ir
ìençtiskiem, imûniem un ârçjâs vides faktoriem. Klîniski psoriâzes gadîjumâ ir izplatîti eritematozi un papulozi infiltratîvi bojâjuma perçkïi
ar izteiktu lobîðanos. Latvijâ psoriâzes izplatîtu formu ârstçðanai ordinç PUVA (psoralçns un ultravioletais starojums A), tâ ir kombinçta
metode, lietojot garo viïòu UVA starojumu 320–400 nm un fotosensibilizatoru 8-metoksipsoralçnu un vidçja garuma viïòu UVB starojuma
ðaura spektra fototerapiju – 311 nm ar specializçtâm TL-01 lampâm. Tomçr ðaurâ spektra UV starojuma terapijai (UVB 311 nm) piemît
izteiktâka imûnsupresîva un pretiekaisuma iedarbîba. Mûsu klîniskâ darba mçríis bija noskaidrot ðaurâ spektra fototerapijas (UVB 311 nm)
efektivitâti kompleksas ârstçðanas gaitâ pacientiem ar daþâda smaguma izplatîtiem psoriâtiskiem bojâjumiem, kuri ârstçjâs Âdas un seksuâli
transmisîvo slimîbu klîniskajâ centrâ. Tika apkopoti un analizçti 260 pacientu ar izplatîtu psoriâzi klîniskie dati. Analizçjot klîniskos datus,
pacienti tika sadalîti divâs grupâs, òemot vçrâ psoriâzes smaguma pakâpi. Pirmajâ grupâ tika iekïauti 102 pacienti ar vieglu un vidçji smagu
psoriâzi, kuriem PASI (psoriâzes bojâjuma izteiktîbas indekss) terapijas sâkumâ svârstîjâs no 7 lîdz 18 punktiem. Otrâ grupâ ietilpa 91
pacients ar smagi norisoðu psoriâzi. Ðiem pacientiem PASI variçja no 22,0 lîdz 48,6 punktiem. Ðaurâ spektra vidçjâ viïòu garuma UVB
terapijas (311 nm) kursa ilgums bija individuâls un atkarîgs no psoriâtiskâ bojâjuma uzsûkðanâs un regresa iestâðanâs laika. Pirmajâ ðaurâ
spektra pacientu terapijas grupâ vidçjâ un kumulatîvâ UVB starojuma deva tika noteikta attiecîgi 1.8 ± 0.6 un 21.5 ± 3.8 J/cm2, otrajâ grupâ
attiecîgi 2.2 ± 0.1 un 27.7 ± 8.0 J/cm2. Kontrolgrupai tika izmantoti 67 (44 vîrieði un 23 sievietes) psoriâzes pacientu dati, kuri tika ârstçti,
lietojot PUVA terapiju. Pozitîva terapijas efektivitâte tika konstatçta visiem pacientiem, kuri saòçma UVB fototerapiju. Klîniskâ
izveseïoðanâs tika sasniegta 86.2% pirmâs grupas pacientiem, 82.4% otrâs grupas pacientiem un 80% kontrolgrupas pacientiem. Ðaurâ
spektra (311 nm) UVB fototerapija mûsdienâs ir viena no vadoðajâm patoìençtiskâs ârstçðanas metodçm pacientiem ar izplatîtu psoriâzi.
Tâs efektivitâte ir augsta, panesamîba laba, kâ arî tai nepiemît blaknes un lietoðanas ierobeþojumi, salîdzinot ar tradicionâlo PUVA terapiju.
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